FCGR3A and plasma cell myeloma: Bolzoni M and co-workers [64] further interestingly reported that sorted bone marrow CD14+ CD16+ cells from myeloma patients were more pro-osteoclastogenic than CD14+ CD16− cells in cultures ex vivo.